within Pharmacolibrary.Drugs.ATC.N;

model N03AX24
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.06,
    Cl             = 2.3666666666666665e-05,
    adminDuration  = 600,
    adminMass      = 1500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0327,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0010833333333333333,
    Tlag           = 3600,            
    Vdp             = 0.09359999999999999,
    k12             = 1.09,
    k21             = 1.09
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX24</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cannabidiol (CBD) is a non-psychoactive phytocannabinoid found in Cannabis sativa. It is used as an anticonvulsant for treatment of certain epileptic disorders such as Dravet syndrome and Lennox-Gastaut syndrome, and is an approved medication (as Epidiolex) in the United States and several other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after oral administration of purified cannabidiol solution.</p><h4>References</h4><ol><li><p>Gundugurti, PR, et al., &amp; Kothapalli, KS (2024). Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial. <i>Asian journal of psychiatry</i> 97 104073–None. DOI:<a href=\"https://doi.org/10.1016/j.ajp.2024.104073\">10.1016/j.ajp.2024.104073</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38797087/\">https://pubmed.ncbi.nlm.nih.gov/38797087</a></p></li><li><p>Schwotzer, D, et al., &amp; Lefever, T (2023). Pharmacokinetics of Cannabidiol in Sprague-Dawley Rats After Oral and Pulmonary Administration. <i>Cannabis and cannabinoid research</i> 8(2) 360–373. DOI:<a href=\"https://doi.org/10.1089/can.2022.0121\">10.1089/can.2022.0121</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36301522/\">https://pubmed.ncbi.nlm.nih.gov/36301522</a></p></li><li><p>Della Rocca, G, et al., &amp; Di Salvo, A (2022). Pharmacokinetics of cannabidiol following single oral and oral transmucosal administration in dogs. <i>Frontiers in veterinary science</i> 9 1104152–None. DOI:<a href=\"https://doi.org/10.3389/fvets.2022.1104152\">10.3389/fvets.2022.1104152</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36686155/\">https://pubmed.ncbi.nlm.nih.gov/36686155</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX24;
